Haematinics
[Haematinics ]
EPTIS Ringversuch Nr. 142620 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts142620 https://www.eptis.bam.de/pts142620
| Name des Anbieters | ||||||||||||||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||
| Sprache(n) | ||||||||||||||||||||||||||||
| Anmerkungen | The Haematinic panel of tests are often undertaken on routine Immunoassay and spectrophotometric platforms used by Medical Biochemistry Departments and are no longer confined to specialist Haematology Departments. Ferritin is used as an indicator of iron status. A ferritin of <30ug/L is indicative of iron deficiency, whilst an elevated level (>400 ug/L) is indicative of iron overloading such as haemosiderosis or haemochromatosis. Elevated ferritin values are also encountered in certain tumours: acute leukaemia, Hodgkins disease and carcinoma of the lung, colon, liver and prostate. Investigation of folate deficiency may be indicated when nutritional, macrocytic or megaloblastic anaemias are suspected. Since a deficiency of either vitamin B12 or folate can cause megaloblastic anaemia, both tests are indicated in order to diagnose the aetiology of anaemia. Four liquid human serum samples are distributed monthly, with a minimum of 48 samples distributed over the year covering a wide clinically relevant range. The material is prepared from endogenous samples donated by polycythaemic, hemochromatosis, renal patients and healthy volunteers. The samples consist of a panel of 10 samples distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Additional challenging samples spiked with iron traceable to NIST SRM #928 are distributed to assess the performance at mild and severely toxic levels. Key Features: - Commutable, endogenous samples from patients and volunteers. - Challenging samples assess the performance at mild and severely toxic levels of iron. - Liquid human serum samples require no pre-analytical preparation. - Sample cover a wide clinically relevant range. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/eqa/haematinics/ or contact@weqas.com | |||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | This Programme covers the main parameters assayed by Biochemistry Departments. | |||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||||||||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 4 x 1.0mL.) | |||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 1996 | |||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.